Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]BF4 PET Imaging for hNIS Expression
NCT02907073Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Sep 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of 18F-tetrafluoroborate in multiple myeloma (MM) and endometrial cancer (EC) (3 arms), sponsored by Mayo Clinic. Primary endpoint: Evaluation of Tissue Distribution of F-18 BF4 in Healthy Volunteers. Started Sep 2016; status: terminated.
02
Drugs
18F-tetrafluoroborate
03
Conditions
multiple myeloma (MM)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT02907073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02907073.